Squarepoint Ops LLC Boosts Stock Holdings in Sight Sciences, Inc. (NASDAQ:SGHT)

Squarepoint Ops LLC lifted its position in Sight Sciences, Inc. (NASDAQ:SGHT - Free Report) by 314.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 169,211 shares of the company's stock after buying an additional 128,355 shares during the period. Squarepoint Ops LLC owned about 0.33% of Sight Sciences worth $616,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Renaissance Technologies LLC grew its stake in Sight Sciences by 654.3% in the fourth quarter. Renaissance Technologies LLC now owns 393,006 shares of the company's stock valued at $1,431,000 after purchasing an additional 340,906 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Sight Sciences by 53.4% during the 4th quarter. Wells Fargo & Company MN now owns 16,600 shares of the company's stock worth $60,000 after acquiring an additional 5,781 shares during the period. Dimensional Fund Advisors LP lifted its stake in Sight Sciences by 79.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 243,954 shares of the company's stock worth $887,000 after purchasing an additional 108,001 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Sight Sciences by 10.7% during the 4th quarter. American Century Companies Inc. now owns 51,564 shares of the company's stock valued at $188,000 after acquiring an additional 4,964 shares in the last quarter. Finally, B Group Inc. bought a new position in shares of Sight Sciences during the 4th quarter worth approximately $2,291,000. 55.51% of the stock is owned by institutional investors.

Insider Buying and Selling at Sight Sciences

In related news, CEO Paul Badawi sold 24,174 shares of Sight Sciences stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $2.30, for a total transaction of $55,600.20. Following the completion of the sale, the chief executive officer now owns 6,010,580 shares in the company, valued at $13,824,334. This trade represents a 0.40% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Manohar K. Raheja acquired 10,000 shares of the stock in a transaction on Wednesday, March 12th. The stock was bought at an average cost of $2.73 per share, with a total value of $27,300.00. Following the completion of the transaction, the executive vice president now owns 145,000 shares in the company, valued at $395,850. This trade represents a 7.41% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 35,196 shares of company stock valued at $81,001 in the last quarter. 30.90% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on SGHT shares. Piper Sandler reduced their target price on Sight Sciences from $5.50 to $3.50 and set a "neutral" rating for the company in a report on Thursday, March 6th. Stifel Nicolaus dropped their target price on shares of Sight Sciences from $5.00 to $4.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. Needham & Company LLC reaffirmed a "hold" rating on shares of Sight Sciences in a research report on Wednesday, April 9th. Citigroup reissued a "neutral" rating and set a $3.60 price target (up previously from $3.20) on shares of Sight Sciences in a research report on Thursday, May 22nd. Finally, Lake Street Capital upped their price objective on Sight Sciences from $2.50 to $3.00 and gave the company a "hold" rating in a research report on Friday, May 9th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $4.02.

Sight Sciences Price Performance

Shares of SGHT stock traded up $0.02 during trading hours on Friday, hitting $4.22. The stock had a trading volume of 60,019 shares, compared to its average volume of 214,656. The stock has a market capitalization of $218.16 million, a price-to-earnings ratio of -4.14 and a beta of 2.46. Sight Sciences, Inc. has a one year low of $2.03 and a one year high of $8.45. The stock's 50-day moving average price is $3.00 and its two-hundred day moving average price is $3.09. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.18 and a quick ratio of 9.74.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.01. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. The company had revenue of $17.51 million for the quarter, compared to analyst estimates of $16.51 million. Equities analysts forecast that Sight Sciences, Inc. will post -0.99 EPS for the current year.

Sight Sciences Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.